摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(6-bromopyridazin-3-yl)propan-2-ol | 1303968-01-5

中文名称
——
中文别名
——
英文名称
2-(6-bromopyridazin-3-yl)propan-2-ol
英文别名
——
2-(6-bromopyridazin-3-yl)propan-2-ol化学式
CAS
1303968-01-5
化学式
C7H9BrN2O
mdl
——
分子量
217.065
InChiKey
KMIAQERZDIGIAH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    46
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-(6-bromopyridazin-3-yl)propan-2-ol 、 5-methyl-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)phenyl)-1H-pyrazole-3-carboxamide 在 potassium phosphate 、 XPhos Pd G2 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以22%的产率得到1-(4-(4-(6-(2-hydroxypropan-2-yl)pyridazin-3-yl)benzyl)phenyl)-5-methyl-1H-pyrazole-3-carboxamide
    参考文献:
    名称:
    DIPHENYL DERIVATIVES AND USES THEREOF
    摘要:
    本公开提供了一种公式(I)的化合物: 或其药用可接受的盐,以及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退化和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
    公开号:
    US20190077773A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
    申请人:MERCK SHARP & DOHME
    公开号:WO2014081619A1
    公开(公告)日:2014-05-30
    The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    本发明涉及嘧啶化合物,这些化合物用作治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统障碍的治疗剂。本发明还涉及使用这些化合物来治疗神经和精神障碍,如精神分裂症、精神疾病或亨廷顿病,以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
  • PYRIMIDINE PDE10 INHIBITORS
    申请人:MCCOMAS Casey C.
    公开号:US20150307489A1
    公开(公告)日:2015-10-29
    The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    本发明涉及嘧啶化合物,其可作为治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经和精神障碍,如精神分裂症、精神病或亨廷顿病,以及与纹状体功能低下或基底节功能障碍相关的疾病。
  • Diphenyl derivatives and uses thereof
    申请人:NOVARTIS AG
    公开号:US10633350B2
    公开(公告)日:2020-04-28
    The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    本公开提供了一种式 (I) 的化合物: 或其药学上可接受的盐,及其在激活生长因子途径、促进伤口愈合、促进组织修复和治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经变性和肌肉萎缩方面的治疗用途。本公开进一步提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
  • US9663513B2
    申请人:——
    公开号:US9663513B2
    公开(公告)日:2017-05-30
  • [EN] DIPHENYL DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE DIPHENYLE ET UTILISATIONS ASSOCIÉES
    申请人:NOVARTIS AG
    公开号:WO2019053090A1
    公开(公告)日:2019-03-21
    The present disclosure provides a compound of formula (I): (I); or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
查看更多